

LIFESPOT HEALTH

ASX:LSH

Annual General Meeting

11:00 am AEST, Thursday 24 May 2018

Seasons Botanic Gardens Hotel, St Kilda Road, Melbourne

Disclaimer

This presentation (the **Presentation**) is provided by Lifespot Health Limited (the **Company** or **LSH**).

Limited Purpose of the Presentation

The Presentation does not purport to contain all information the Recipient may require or consider material in respect of evaluating the Company. Certain information has not been included in the Presentation although the Recipient may consider such information to be necessary to its decision as to whether to participate in a transaction. The information contained in the Presentation is of a general nature only. It has been sourced from publicly available information as well as non-public information. The Company nor any of its other advisors has verified or conducted an independent appraisal of the information contained in the Presentation (including the Forward Looking Statements discussed below) and none of them is under any obligation to correct, update or revise the Presentation or any information in it. The Recipient must rely on its own independent enquiries in respect of all information contained in the Presentation.

No Liability, Representations or Warranties

The Company nor any of their directors, officers, employees and advisors shall have any liability (whether arising from negligence or otherwise) for any representations or warranties (expressed or implied) or any information contained in or any omissions from, the Presentation (including Forward Looking Statements) or any written or oral communications transmitted to the Recipient in the course of its evaluation of any transaction, and makes any representations or warranty, expressed or implied as to the accuracy, completeness or thoroughness of any information contained in the Presentation or any other information provided to the Recipient.


Forward Looking Information

The Presentation may also contain quantitative statements of anticipated future performance such as projections, forecasts, calculations, forward-looking statements or estimates all of which are based on certain assumptions (Forward Looking Statements). The Forward Looking Statements involve subjective judgements and are based on a large number of assumptions and are subject to significant uncertainties and contingencies, many of which are outside the control of the Company and may not prove to be correct. No representation or warranty is made that any Forward Looking Statements will be achieved or occur or that the assumptions upon which they are based are reasonable or the financial calculations from which they have been derived are correct. Actual future events may vary significantly from the Forward Looking Statements. Each Recipient should undertake its own independent review of the Forward Looking Statements, including assumptions on which they are based and the financial calculations from which they are derived.

Our Mission

To increase the quality of life of patients from;

- Improved treatment via instantaneous transmission of accurate and meaningful data
- Intelligent use of technology and systems to provide feedback and coaching via their healthcare professional
- Facilitated control of relatives in need of care
- Safe and accurate dosing of the right medication at the right time



Company Achievements

1. 2017 Revenue \$A535k, R&D investment \$A1,213
2. Strong balance sheet with cash of \$4.5m as at 31 December 2017
3. Fully functional and maintained Body-Tel medical software
4. Certified Quality Management System (QMS) under ISO 13485
5. Operating according to the IEC/EN 62304 standard
6. Key Accounts – B.Braun & Buerer growing project revenue & strong pipeline
7. Seng-Vital Cannabis JV and potential MOU with Cannabis Co's
8. Slowing cash burn from sales growth and “team right sizing” in 2018
9. Positive outlook for break even in 2018 and profitable 2019



Life-spot Health Asset development

Asset	Description	Ownership	Development stage
Body-Tel®	Facilitates management of chronic diseases with accurate & compliant measurement of vitals	100%	<ul style="list-style-type: none">Commercialisation scale-up for devices and chronic disease
Seng-Vital®	Smart Vaporizer for Cannabis oils or herbs integrated BodyTel to allow both patients and authorized physicians to retrieve and evaluate the data for safety, compliance and administration	50%	<ul style="list-style-type: none">MOU under discussion for Cannabis Clinical TrialsGolden sample proto-type ready in July
Life-Spot®	Diagnostic support of classic skin diseases	100%	<ul style="list-style-type: none">On-hold

Body-Tel GMBH - Capability

- Digitalisation of vitals from “sensor to cloud” (compliant digital health record)
 - Bluetooth sensor digitalisation
 - App development for iOS and Android
 - Back-end customization on Azure Cloud
 - Web development
 - Bluetooth simulator development
 - Analyse of vital parameter
 - Support safe and accurate medical and lifestyle interventions
-
- Head office: Bad Wildungen (13 employees)
 - Parent company: Lifespot Health in Australia: Melbourne (2 Directors & 1 Company Secretary)

Features of the BodyTel Digital Platform


- Closed loop patient & device management system
- Identity management (stores patient data separately)
- Dashboard (overview)
- Diary of measured values
- Manual entry and editing of measured values
- Graphical evaluation of measured values
- Statistics
- Tele-monitoring of “friends & family” in a non-professional environment
- Healthcare Professional Views

Revenue Model

Stage / Segment	Diagnostics	Disease	Medication
	Diagnostic device manufacturers	Pharmaceutical companies	Drug innovators
1. Development fee	✓	Body-Tel platform	Body-Tel platform
2. Monthly Licence & Maintenance	✓	✓	✓
3. Body-Tel cloud based data management and per user access	✓	✓	✓


Body Tel Architecture

- ✓ ISO 13485
- ✓ IEC/EN 62304 standard










Diagnostic Hardware Connectivity

Vital	B.Braun	Beurer	Roche
Blood sugar	Omnitest 5 BT	GL50 Evo	
Blood Pressure		BC85, BM85, BM95	
Blood Coagulation			CoaguChek
Body mass / fat		BF710, BF 800	
Blood saturation		PO60	
ECG		ME90, BM95	



- Supported
- In development

Case Study: Diabetes



Drug delivery device connectivity

Drug	Seng Vital
Cannabis	Cannamed*



* In development – July 2018 ready

Seng-Vital® - Capability

- Vapes Cannabis oil or flower
- Embedded in BodyTel platform for safety, compliance and data collection
- Unique fingerprint security
- Strong candidate for USA FDA approval

Business Development strategy 2018-2020

Segment	Diagnostic	Disease	Medication
	Diagnostic device manufacturers	Pharmaceutical companies	Drug innovators
Opportunity	Provide world class software development and maintenance services with ISO / QMS certified data collection, storing and reporting	Support drug safety, compliance and new data driven patient insights for diabetes, CVD and other lifestyle driven treatments	Provide world standard accurate data collection services for clinical trials and subsequent drug approval
Companies	<ul style="list-style-type: none"> • B Braun (existing) • Beurer (existing) • Roche (existing) • Inotexx (existing) • Abbott • Omron • etc 	<ul style="list-style-type: none"> • Several Pharma Companies • Pharmacy chains • Community programs • Disease focussed organisations 	<ul style="list-style-type: none"> • Cannabis Companies (Seng-Vital)

Growth plans

1. Accelerate Body Tel platform sales growth from
 - Current Key Accounts – Ongoing
 - Develop new accounts in device manufacturers
 - Develop disease focussed sales with Pharma Co's and Payers in EU and Asia Pac
 - Employ EU Business Development Manager / Sales Director – August 2018
 - Therapeutic Goods Administration (TGA) Australia registration
2. Optimise resources to ensure right sizing to achieve positive cash flow
3. Partner with Cannabis companies to realise value in Seng-Vital JV